rVSV-ZEBOV
E85063
Ebola vaccine
live attenuated vaccine
recombinant viral vector vaccine
vesicular stomatitis virus-based vaccine
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
All labels observed (4)
| Label | Occurrences |
|---|---|
| rVSV-ZEBOV canonical | 4 |
| rVSVΔG-ZEBOV-GP | 2 |
| rVSV-ZEBOV Ebola vaccine | 1 |
| rVSV-ZEBOV Ebola vaccine candidate | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T701627 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rVSV-ZEBOV Context triple: [2014–2016 West Africa Ebola outbreak, vaccineUsed, rVSV-ZEBOV]
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo
The 2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo was a major Ebola virus outbreak in the country’s conflict-affected eastern region that became the second-largest Ebola epidemic ever recorded and prompted a global emergency response.
-
C.
TMV
TMV is the stock ticker symbol under which TeamViewer, a global provider of remote connectivity and remote access software, is traded on financial markets.
-
D.
Ehrlich
Ehrlich is a German-origin surname borne by numerous notable individuals across fields such as science, medicine, and the arts.
-
E.
The Germ
The Germ was a short-lived 1850 periodical founded by members of the Pre-Raphaelite Brotherhood to promote their artistic and literary ideals.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: rVSV-ZEBOV Target entity description: rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo
The 2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo was a major Ebola virus outbreak in the country’s conflict-affected eastern region that became the second-largest Ebola epidemic ever recorded and prompted a global emergency response.
-
C.
TMV
TMV is the stock ticker symbol under which TeamViewer, a global provider of remote connectivity and remote access software, is traded on financial markets.
-
D.
Ehrlich
Ehrlich is a German-origin surname borne by numerous notable individuals across fields such as science, medicine, and the arts.
-
E.
The Germ
The Germ was a short-lived 1850 periodical founded by members of the Pre-Raphaelite Brotherhood to promote their artistic and literary ideals.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola vaccine
ⓘ
live attenuated vaccine ⓘ recombinant viral vector vaccine ⓘ vesicular stomatitis virus-based vaccine ⓘ |
| administeredTo | adults ⓘ |
| alsoKnownAs |
Ervebo
ⓘ
V920 ⓘ rVSV-ZEBOV ⓘ
surface form:
rVSVΔG-ZEBOV-GP
|
| category | WHO-recommended Ebola vaccine ⓘ |
| contraindication |
use in certain immunocompromised individuals may be restricted
ⓘ
use in pregnancy may be restricted ⓘ |
| design | recombinant VSV with Ebola virus glycoprotein gene replacing VSV glycoprotein gene ⓘ |
| developedFor | protection against Ebola virus infection in humans ⓘ |
| dosageForm | injectable suspension ⓘ |
| efficacyDemonstratedIn | ring vaccination trial in Guinea ⓘ |
| expressesAntigen | Ebola virus glycoprotein ⓘ |
| geographicUse |
Democratic Republic of the Congo
ⓘ
Guinea ⓘ Liberia ⓘ Sierra Leone ⓘ |
| immuneResponseType |
cell-mediated immune response
ⓘ
humoral immune response ⓘ |
| indicatedFor | individuals at risk of exposure to Ebola virus ⓘ |
| licensedTo | NewLink Genetics ⓘ |
| marketingAuthorizationHolder | Merck & Co. ⓘ |
| mechanismOfAction | induces immune response against Ebola virus glycoprotein ⓘ |
| originalDeveloper | Public Health Agency of Canada ⓘ |
| publicHealthUse | ring vaccination strategy around confirmed Ebola cases ⓘ |
| regimen | single-dose vaccination ⓘ |
| regulatoryStatus |
received WHO prequalification
ⓘ
received regulatory approvals in multiple countries ⓘ |
| riskGroupUse |
healthcare workers at risk of Ebola exposure
ⓘ
laboratory personnel handling Ebola virus ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| safetyProfile | commonly causes transient injection-site and systemic reactions ⓘ |
| sponsorInKeyTrials |
Guinean Ministry of Health
ⓘ
Norwegian Institute of Public Health ⓘ World Health Organization ⓘ |
| storageRequirement | requires cold-chain storage ⓘ |
| subsequentlyDevelopedBy | Merck & Co. ⓘ |
| targetDisease | Ebola virus disease ⓘ |
| targetPathogen | Zaire ebolavirus ⓘ |
| targetStrain |
Zaire ebolavirus
ⓘ
surface form:
Ebola virus Zaire strain
|
| trialDesign | cluster-randomized ring vaccination trial ⓘ |
| trialPhase | Phase III clinical trial ⓘ |
| trialPopulation | contacts and contacts-of-contacts of Ebola cases ⓘ |
| usedDuringOutbreak |
2014–2016 West Africa Ebola outbreak
ⓘ
surface form:
2014–2016 West African Ebola outbreak
2018–2020 Ebola outbreaks in the Democratic Republic of the Congo ⓘ |
| vaccineType | replication-competent viral vector vaccine ⓘ |
| vaccineVector | vesicular stomatitis virus ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: rVSV-ZEBOV Description of subject: rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
Referenced by (8)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
rVSV-ZEBOV Ebola vaccine
this entity surface form:
rVSVΔG-ZEBOV-GP
this entity surface form:
rVSVΔG-ZEBOV-GP
this entity surface form:
rVSV-ZEBOV Ebola vaccine candidate